Keep, but to get to the testing phase for efficacy, you first have to get through all of the other protocols. I think you're wrong that the stock will go nowhere until. As milestones are hit confidence will build and people will buy. New IND's, trials and patents could also raise the value of the company. Of course outside of the science and product side of things there are/were some significant management issies that also could put a damper on the stock even if there is efficacy - it is nice to see these being resolved, seeing that we have the funding to complete the trials, a high quality BOD and a plan around the sahre structure.
Wow, Theres, it's good to see you being so positive about ACTC, but I still believe it'll take the proof of efficacy before this stock really takes off. And I don't mean that the revenues need to be there, just the proof that it works will send this stock soaring higher, and the proof of efficacy will also kick in irrational exuberance, making it anyone's guess how high this stock will go. And I'm thinking that sometime this fall things will really begin to fall in place for ACT, and it's shareholders.